Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
CONCLUSION: Our findings suggest that cost-effective and clinically optimal treatment strategies are RT alone for standard-risk DCIS and observation for good-risk DCIS, with personalization on the basis of patient age and preference for RT. Hormonal therapy is likely suboptimal for most patients with DCIS.PMID:34019456 | DOI:10.1200/JCO.21.00831
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Apar Gupta Sachin R Jhawar Mutlay Sayan Zeinab A Yehia Bruce G Haffty James B Yu Shi-Yi Wang Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Hormonal Therapy | Hormones | Tamoxifen | USA Health | Women